Skip to content

Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility

Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07653945
Enrollment
206
Registered
2026-06-17
Start date
2026-07-01
Completion date
2026-12-31
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Lesion, Biopsy-related Bleeding, Bronchoscopic Biopsy

Keywords

Bronchoscopy, Biopsy, Hemorrhage, Optical Imaging

Brief summary

The goal of this observational study is to learn whether red dichromatic imaging (RDI) can help doctors see the bronchoscopic field more clearly after a biopsy. The study will include adults who need a bronchoscopic biopsy because doctors can see an abnormal area inside the airway.During a bronchoscopic biopsy, bleeding can happen after tissue is taken. Blood may cover the biopsy area and make it harder for doctors to see where to continue the procedure. RDI is an imaging mode that uses special colors of light to help show blood-covered areas more clearly.The main question this study aims to answer is:Does RDI improve visibility of the bronchoscopic field after bleeding caused by bronchoscopic biopsy? Researchers will compare images taken with standard white light imaging and RDI during the same bronchoscopy procedure. Both types of images will be taken after the first biopsy and before any field-clearing treatment is done. Participants will have bronchoscopic biopsy as part of their regular medical care, have images taken using standard white light imaging and RDI during the same procedure, have routine follow-up for possible medical problems after bronchoscopy. Taking part in this study will not add extra biopsies or change the participant's regular medical care.

Interventions

DEVICERed Dichromatic Imaging (RDI)

Red dichromatic imaging (RDI) is an optical imaging mode used during bronchoscopy. In this observational study, RDI images and standard white light imaging images will be collected during the same clinically indicated bronchoscopy procedure after the biopsy. RDI will be evaluated for its ability to improve post-biopsy bronchoscopic field visibility. The study will not assign participants to treatment groups, add extra biopsies, or change routine clinical care.

Sponsors

First Affiliated Hospital of Ningbo University
Lead SponsorNETWORK
Shanghai Chest Hospital
CollaboratorOTHER
Anhui Chest Hospital
CollaboratorOTHER
Huzhou Central Hospital
CollaboratorOTHER
The Second Affiliated Hospital of Jiaxing University
CollaboratorOTHER
Lanxi Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Zhoushan Hospital of Zhejiang
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18 years. 2. Visible abnormal endobronchial lesion under bronchoscopy, including endobronchial neoplasm, mucosal abnormality, airway stenosis, or other lesion requiring biopsy to determine its nature. 3. Provision of informed consent to participate in this clinical study and signing of the informed consent form.

Exclusion criteria

1. Presence of contraindications to bronchoscopy, such as severe cardiopulmonary disease, coagulation dysfunction (including patients receiving anticoagulant therapy and/or anticoagulant drugs who have not discontinued these drugs for more than 5 days before the examination), poor tolerance of anesthesia, psychiatric disease, or severe neurosis. 2. Intra-procedural decrease in SpO₂ or inability to tolerate bronchoscopy. 3. Obvious airway bleeding observed during bronchoscopy that may increase the risk of worsening the patient's condition. 4. Images that are obviously blurred or out of focus, or that contain severe reflection, bubbles, or instrument obstruction, making subsequent image analysis impossible. 5. Inability to cooperate with the study for any reason, or any other condition that the investigator considers unsuitable for study participation.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of post-biopsy bronchoscopic fields judged suitable for direct procedural continuationPeriproceduralPaired white light imaging and red dichromatic imaging images will be assessed by independent evaluators. A bronchoscopic field will be judged suitable for direct procedural continuation if the biopsy site, lesion surface, or lesion boundary remains identifiable and biopsy or subsequent bronchoscopic procedures can continue without additional field-clearing intervention.

Secondary

MeasureTime frameDescription
Visual distinguishability score between the bleeding area and surrounding blood-covered backgroundPeriproceduralPaired white light imaging and red dichromatic imaging images will be assessed by independent evaluators. The visual distinguishability between the biopsy-related bleeding area and the surrounding blood-covered background will be scored on a 4-point scale. A score of 1 indicates that the two areas are almost indistinguishable, and a score of 4 indicates that the two areas are clearly distinguishable and easy to identify.
Objective color difference between the bleeding area and surrounding blood-covered backgroundPeriproceduralObjective color difference will be measured using paired white light imaging and red dichromatic imaging images. Regions of interest will be selected from the biopsy-related bleeding area and the surrounding blood-covered background. Color parameters will be measured in the CIE 1976 L\*a\*b\* color space, and the overall color difference will be calculated as ΔE. Differences in the L\*, a\*, and b\* channels may also be analyzed.

Countries

China

Contacts

CONTACTZhongbo Chen
leonczb@163.com86+13777125910

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026